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Abstract
Introduction: The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG)
genes in the susceptibility and phenotype expression of systemic sclerosis (SSc).
Methods: In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations (Spain,
Germany, The Netherlands, and Italy) were included in the study. Five single-nucleotide polymorphisms (SNPs) of
CD40 (rs1883832, rs4810485, rs1535045) and CD40LG (rs3092952, rs3092920) were genotyped by using a
predesigned TaqMan allele-discrimination assay technology. Meta-analysis was assessed to determine whether an
association exists between the genetic variants and SSc or its main clinical subtypes.
Results: No evidence of association between CD40 and CD40LG genes variants and susceptibility to SSc was
observed. Similarly, no significant statistical differences were observed when SSc patients were stratified by the
clinical subtypes, the serologic features, and pulmonary fibrosis.
Conclusions: Our results do not suggest an important role of CD40 and CD40LG gene polymorphisms in the
susceptibility to or clinical expression of SSc.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease of the
connective tissue characterized by excessive fibrosis of
the dermis and vascular damage. It also affects internal
organs, such as the lung, gastrointestinal, and vascular
systems [1]. SSc is a complex polygenic disease in which
environmental and genetic factors are involved in the
susceptibility to this disease. Candidate gene and gen-
ome-wide association studies (GWASs) performed in
SSc have identified new loci implicated in the suscept-
ibility to SSc [2]. Nevertheless, the complete genetic
components of SSc remain unknown.
CD40 is a member of the tumor necrosis factor recep-
tor superfamily (TNFR), and it is expressed on the sur-
face of several immune and nonhematopoietic cells,
such as B cells, macrophages, dendritic cells, fibroblasts,
and endothelial cells in certain pathogenic conditions
[3]. Its ligand, CD40LG (CD154), is expressed mainly on
the surface of CD4+ T cells. CD40-CD40LG interactions
are necessary for the activation of both humoral and cel-
lular immune responses [3]. The CD40-CD40LG path-
way has been suggested to play an important role in the
pathogenesis of autoimmune diseases [4]. An increase of
soluble CD40LG (sCD40LG) has been observed in many
autoimmune diseases, such as systemic lupus erythema-
tosus (SLE) [5], rheumatoid arthritis (RA) [6], and
Graves disease (GD) [7]. Interestingly, patients with SSc
and limited cutaneous disease have higher levels of
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sCD40LG in the plasma than those of the diffuse cuta-
neous disease [8]. Similarly, high levels of CD40 protein
were observed in both the plasma [9] and the cell sur-
face of skin fibroblasts [10] from SSc patients. In addi-
tion, previous studies reported the association of CD40
polymorphisms with susceptibility to a number of auto-
immune diseases, such as GD [11], multiple sclerosis
[12], RA [13,14], Crohn disease [15], and with visual
ischemic manifestations in individuals with biopsy-pro-
ven giant cell arteritis [16]. Nevertheless, in the case of
SLE, contradictory data exist [17-19]. In addition, muta-
tions of CD40LG were observed in patients with the
hyper-immunoglobulin M (IgM) syndrome [20], and
genetic variations located at the 3UTR of the CD40LG
gene were associated with two autoimmune diseases,
SLE [21] and RA [22].
Taking into account these considerations, we aimed to
investigate the potential association of CD40 and
CD40LG genes polymorphism with SSc.
Materials and methods
Patients
In total, 2,670 SSc patients and 3,245 healthy individuals
from four European populations were included in this
study (Spain: cases, 1,103; controls, 1,610; Germany:
cases, 554; controls, 437; The Netherlands: cases, 380;
controls, 489; Italy: cases, 633; controls, 709). All the
patients fulfilled the 1980 American College of Rheuma-
tology (ACR) classification criteria for SSc [23]. Limited
cutaneous disease (lcSSc) was defined as definite skin
thickening confined to the distal extremities, whereas
cases of diffuse cutaneous disease (dcSSc) required also
the involvement of skin proximal to the knees and
elbow [24,25]. Measurement of main SSc-specific auto-
antibodies, anti-centromere antibodies (ACAs), and anti-
topoisomerase I antibodies (ATAs), was performed by
using standard methods. Pulmonary fibrosis data were
investigated by using a computed tomography scan. The
main features of all populations included in this study
were previously reported [26-28].
Patients and controls were included in the study after
written informed consent, according to the declaration
of Helsinki. The study was approved by local ethical
committees from all the participating centers.
SNPs selection and genotyping
DNA from patients and controls was obtained by using
standard methods. CD40 is located on chromosome
20q13.12. Three single-nucleotide polymorphisms
(SNPs) of CD40 associated with other autoimmune dis-
eases were selected. rs1883832 had been associated with
GD [11]; whereas rs4810485, in linkage disequilibrium
with rs1883832 (r2 = 0.95), has been identified as a new
risk factor for RA [13]. Furthermore, rs1535045 has
been associated with subclinical atherosclerosis in dia-
betes families [29]. CD40LG is found on chromosome
Xq26.3. Two genetic variants located in 5 UTR
(rs3092952) and 3 UTR (rs3092920) of CD40LG (r2 =
0.38) were selected. These SNPs are located in different
haplotype blocks of CD40LG [17]. The variant
rs3092920 is located near the 3 UTR microsatellite,
which was previously associated with RA and SLE
[21,22]; whereas rs3092952 is a functional variant related
to the levels of sCD40LG in plasma [30].
All SNPs were genotyped in the same center by using
a TaqMan SNP genotyping assay in a 7900HT Real-
Time polymerase chain reaction (PCR) system, by fol-
lowing the conditions recommended by the manufac-
turer (Applied Biosystems, Foster City, CA, USA).
About 10% of the patients were genotyped twice to ver-
ify the genotyping consistency, showing 99% identical
genotypes. The genotyping call-rate success was >95%
for both cases and controls in all populations.
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) was tested by
means of the Fisher Exact test or c2 when necessary.
The case-control association study was performed by
using a 2 × 2 contingency table with c2 to obtain P
values, odds ratios (ORs), and 95% confidence intervals
(CIs). Combined OR was calculated according to a
fixed-effects model (Mantel-Haenszel meta-analysis),
and the heterogeneity of OR among all populations was
calculated by using the Breslow-Day test. P values <0.05
were considered statistically significant. Statistical ana-
lyses were carried out with PLINK [31].
The estimation of the power of the study to detect an
effect of a polymorphism in disease susceptibility was
performed by using The CaTS Power Calculator soft-
ware [32].
Results
CD40 gene variants in SSc
Three CD40 polymorphisms were genotyped in four
European populations. First, we analyzed the cohorts
individually and then combined the samples in a pooled
analysis. Table 1 describes allelic distribution of the
three SNPs in the pooled analysis, and Additional file 1,
Table S1-3 contains detailed data for each population.
Both cases and controls were confirmed to be in HWE
in all populations. No evidence of association between
CD40 polymorphisms and susceptibility to SSc was
observed in the pooled analysis (allelic P value
rs1883832: P = 0.61; OR, 1.02; 95% CI, 0.94 to 1.11;
rs4810485: P = 0.42; OR, 1.04; 95% CI, 0.95 to 1.13;
rs1535045: P = 0.275; OR, 0.95; 95% CI, 0.88 to 1.04).
To investigate the possible influence of the CD40
polymorphisms with clinical features, we stratified the
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patients according to the main SSc manifestations. How-
ever, we did not observe evidence of association after
comparing lcSSc and dcSSc with healthy subjects (see
Table 1). Additionally, we compared the presence of
SSc-specific autoantibodies in the patients with the
healthy individuals, but no significant differences were
observed (Table 1). Likewise, no significant association
was observed when patients with pulmonary fibrosis
were compared with healthy controls (Table 1).
CD40LG gene variants in SSc
Because CD40LG is located on the X-chromosome and
shows the sexual bias of this disease, we performed the
analysis separately for each gender. Table 2 shows the
allelic frequencies in SSc females of the two CD40LG
polymorphisms in the pooled analysis, and Additional
file 1, Table S4-5 shows the frequencies for each popula-
tion. Deviations from HWE were not observed. With the
Mantel-Haenzel test, the genotype and allele frequencies
were similar between SSc patients and healthy indivi-
duals (allelic P value rs3092952: P = 0.44; OR, 0.96; 95%
CI, 0.85 to 1.07; rs3092920: P = 0.565; OR, 0.96; 95% CI,
0.83 to 1.11). No statistical differences were observed
when SSc patients were stratified by common subtype of
the disease, the presence of SSc-specific autoantibodies,
and pulmonary fibrosis (Table 2).
In addition, we analyzed these two polymorphisms in
SSc male patients, but no evidence of association was
found in the combined analyses (see Additional file 1,
Table S6-7). However, these results should be inter-
preted with caution because the statistical power is
insufficient to detect association because of low sample
size.
Discussion
The important role of the CD40-CD40LG pathway in
autoimmunity [4], together with the association of the
CD40 gene with a number of autoimmune diseases,
prompted us to investigate for the first time the contri-
bution of CD40 and CD40LG genes in SSc.
Despite the previous findings [8-10], we observed no
evidence of association of the CD40 or CD40LG gene
variants analyzed with SSc. It was also the case when
SSc patients were stratified by the SSc clinical subtypes,
specific autoantibodies, or pulmonary fibrosis. We ana-
lyzed a large European population from four different
countries to increase the robustness of the study. In this
regard, our combined study had an estimated power of
92% to detect the relative risk, with OR of 1.15 obtained
for RA susceptibility [13,14], at the 5% significance level.
Therefore, it seems unlikely that the absence of associa-
tion found in our study would be due to Type II error.
Table 1 Pooled analysis of CD40 polymorphisms
SNP Change Samples set N Minor allele,
no. (frequency)
P value OR [95% CI] P-BD
rs1883832 T/C Controls 3,138 1,427 (0.277)
SSc 2,605 1,424 (0.274) 0.610 1.02 [0.94-1.11] 0.904
lcSSc 1,758 987 (0.276) 0.246 1.06 [0.96-1.16] 0.496
dcSSc 860 451 (0.271) 0.683 0.97 [0.86-1.10] 0.446
ACA + 1,077 592 (0.261) 0.879 1.01 [0.90-1.13] 0.355
ATA + 716 416 (0.293) 0.108 1.11 [0.98-1.26] 0.946
Pulmonary fibrosis 702 394 (0.278) 0.433 1.05 [0.92-1.20] 0.802
rs4810485 G/T Controls 3,122 1,652 (0.272)
SSc 2,560 1,388 (0.274) 0.420 1.04 [0.95-1.13] 0.935
lcSSc 1,736 967 (0.277) 0.155 1.07 [0.97-1.18] 0.481
dcSSc 839 436 (0.269) 0.817 0.99 [0.87-1.12] 0.600
ACA + 1,071 580 (0.257) 0.844 1.01 [0.90-1.13] 0.399
ATA + 699 402 (0.292) 0.080 1.12 [0.99-1.28] 0.890
Pulmonary fibrosis 682 375 (0.272) 0.483 1.05 [0.92-1.20] 0.605
rs1535045 T/C Controls 3,147 1,595 (0.247)
SSc 2,585 1,272 (0.243) 0.275 0.95 [0.88-1.04] 0.560
lcSSc 1,749 860 (0.251) 0.375 0.96 [0.87-1.05] 0.334
dcSSc 850 411 (0.228) 0.275 0.93 [0.82-1.06] 0.746
ACA + 1,075 525 (0.241) 0.348 0.95 [0.84-1.06] 0.844
ATA + 707 369 (0.264) 0.669 1.03 [0.90-1.18] 0.640
Pulmonary fibrosis 696 340 (0.250) 0.396 0.94 [0.82-1.08] 0.028
Controls are used as reference for all comparisons. All P values have been calculated for the allelic model by using the Mantel-Haenszel test under fixed effect.
P_BD, P value by the Breslow-Day method.
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In the present study, we analyzed the functional CD40-
1C/T polymorphism (rs1883832). This genetic variant is
located at -1 from the ATG, within a Kozak sequence, a
stretch of nucleotides essential for translation that flanks
the start codon in vertebrate genes [33]. The presence of a
major allele (C) in this SNP is associated with the increase
of the efficiency of CD40 translations [11]. Although quan-
titative differences between CD40 mRNA and proteins
have been observed in SSc skin fibroblasts [10], the
absence of association found for rs1883832 suggests that
this variant might not affect the translation of CD40
mRNA. This process may be upregulated in these abnor-
mal skin fibroblasts, or other genes of the CD40 signaling
pathway may influence the CD40 expression. However,
functional studies in this way should be constructed before
excluding an association between this variant and the
CD40 expression in SSc.
Although CD40 might be a common susceptibility
locus for some autoimmune diseases [11-16], our results
do not suggest an important role of CD40 in the sus-
ceptibility to SSc. Several genes have been recently dis-
closed to play a function in the susceptibility to
autoimmune diseases, suggesting that these diseases
share a genetic background [34]. However, these loci
may not be universal genetic factors for autoimmune
disorders; therefore, the autoimmunity might result
from specific and multiple pleiotropic effects [19]. Also,
other genes are unique for each disease, reflecting a spe-
cific etiology [19,34]. Additional studies are required for
the identification of specific and shared genetic path-
ways that contribute to a better understanding of the
pathogenesis of the autoimmune diseases.
The role of the CD40LG in the susceptibility to auto-
immune diseases has not been investigated as broadly as
that of CD40, mainly because this gene is located on the
× chromosome. The different prevalences of these dis-
eases in both genders can suggest that genes located on
the × chromosome could be susceptibility factors in
autoimmune diseases; however, few studies analyzed
polymorphisms on this chromosome. Mutations on this
gene are associated with X-linked hyper-IgM syndrome,
a familial genetic disorder characterized by an increase
of IgM level and a decrease of IgG and IgA [20], but in
SLE, no evidence of association has been found [17].
Similarly, our results show that the CD40LG gene may
not be SSc susceptibility loci.
Conclusions
Our results do not suggest an important role of CD40
and CD40LG genes in the susceptibility to SSc. Addi-
tional studies are required to draw firm conclusions
about the exact role of the CD40 and CD40LG genes in
SSc susceptibility because other variants might be
involved in SSc. Future studies involving other genes of
the CD40-CD40LG pathway should be conducted to
elucidate fully the contribution of this pathway in the
pathogenesis of SSc.
Additional material
Additional file 1: Supplementary Tables 1 through 7. Genotype and
allele distribution of the CD40 and CD40LG polymorphisms for each
population included in the current study.
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